Oukangvision Bio-B (01477): Fluoroclone intravitreal implant approved by the State Drug Administration for production in mainland China

According to the Zhitong Finance App, Oukangweishi Bio-B (01477) announced that the group's fluorine intravitreal implants have recently been approved by the China Drug Administration for production in mainland China.

The product submitted a registration application under the Class 4 chemical drug route and was included in the priority review and approval process for drug marketing licenses by the State Drug Administration; its production technology was obtained by the Group through technology transfer, and process transfer and process verification have been completed.